A Phase I/II Open Label, Multicenter Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Pexidartinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Company; Plexxikon
- 18 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Jul 2017 Planned primary completion date changed from 1 Oct 2019 to 1 Feb 2020.
- 20 Mar 2017 Status changed from not yet recruiting to recruiting.